{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:21:50Z","timestamp":1787797310075,"version":"build-2784847793"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Based on improved invasive disease-free survival in the monarchE trial, the US Food and Drug Administration (FDA) approved abemaciclib for adjuvant treatment of high-risk, estrogen receptor\u2013positive (ER+), human epidermal growth factor receptor 2 (HER2)\u2013negative breast cancer (BC) in combination with endocrine therapy. This study examines real-world prescribing patterns and clinical experiences with adjuvant abemaciclib at an academic cancer center in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This is a retrospective single-institution cohort study that included patients diagnosed between January 2021 and August 2023 with lymph node\u2013positive, stage II-III ER+\/HER2\u2013 BC at the University of Pittsburgh Medical Center who would have met eligibility criteria for the monarchE trial. We assessed tumor, provider, and patient factors associated with abemaciclib prescribing using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Four hundred sixty-eight patients met monarchE eligibility criteria: 271 (58%) were eligible for abemaciclib under the 2021 FDA approval indications, 324 (69%) met monarchE cohort 1, and 144 (31%) met cohort 2 eligibility criteria only. In the entire cohort, 162 (35%) received a prescription, which was higher in patients meeting FDA approval indications (44%) and lower in those meeting only cohort 2 eligibility (20%). Prescribing increased from 28% in 2021 to 42% in 2022 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0097). Younger age at diagnosis, higher nodal burden, and higher tumor size were significantly associated with abemaciclib prescribing. Patient refusal was the primary reason for nonprescription (55%). Among those prescribed abemaciclib, 81% experienced toxicities, 47% required dose modifications, and 20% discontinued treatment before completion, primarily due to diarrhea. Abemaciclib prescription was associated with a 66% lower risk of recurrence after adjustment for age, BMI, nodal status, and other variables.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Adjuvant abemaciclib prescribing was low despite its proven benefits. Further research is needed to address prescribing barriers and understand decision-making factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/oa-25-00076","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:59:08Z","timestamp":1774468748000},"source":"Crossref","is-referenced-by-count":1,"title":["Prescribing Patterns and Real-World Clinical Usage of Adjuvant Abemaciclib for Early-Stage, High-Risk, Estrogen Receptor\u2013Positive Breast Cancer"],"prefix":"10.1200","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-9396","authenticated-orcid":true,"given":"Sneha","family":"Rajendran","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9108-1536","authenticated-orcid":true,"given":"Alexander Chih-Chieh","family":"Chang","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6291-8817","authenticated-orcid":true,"given":"Valerie","family":"Gao","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8804-6990","authenticated-orcid":true,"given":"Faith","family":"Seltun","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Community Osteopathic, Harrisburg, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexi","family":"Lu","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0592-1777","authenticated-orcid":true,"given":"David","family":"Lazris","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6045-588X","authenticated-orcid":true,"given":"Joshua","family":"Wang","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-562X","authenticated-orcid":true,"given":"Kathryn","family":"Demanelis","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"},{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7504-867X","authenticated-orcid":true,"given":"Julia","family":"Foldi","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA"},{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/tbcr-21-27","article-title":"Role of abemaciclib in primary breast cancer: A narrative review of MonarchE","volume":"3","author":"Takahashi N","year":"2022","unstructured":"Takahashi N, Shimizu C, Shimomura A, et al: Role of abemaciclib in primary breast cancer: A narrative review of MonarchE. Transl Breast Cancer Res 3:3, 2022","journal-title":"Transl Breast Cancer Res"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03639"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02554"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.015"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02742"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01994"},{"key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2105\/AJPH.2016.303064","article-title":"Neighborhoods and health: What do we know? What should we do?","volume":"106","author":"Diez Roux AV","year":"2016","unstructured":"Diez Roux AV: Neighborhoods and health: What do we know? What should we do? Am J Public Health 106:430-431, 2016","journal-title":"Am J Public Health"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05333.x"},{"key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ypmed.2014.05.011","article-title":"Neighborhood-level socioeconomic deprivation predicts weight gain in a multi-ethnic population: Longitudinal data from the Dallas Heart Study","volume":"66","author":"Powell-Wiley TM","year":"2014","unstructured":"Powell-Wiley TM, Ayers C, Agyemang P, et al: Neighborhood-level socioeconomic deprivation predicts weight gain in a multi-ethnic population: Longitudinal data from the Dallas Heart Study. Prev Med 66:22-27, 2014","journal-title":"Prev Med"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1802313"},{"key":"e_1_3_9_18_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.520","article-title":"Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial","volume":"43","author":"Desmedt C","year":"2025","unstructured":"Desmedt C, Borgquist S, Garcia-Estevez L, et al: Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients (pts) treated in the monarchE trial. J Clin Oncol 43, 2025 (suppl 16; abstr 520)","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00126"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06029-y"},{"key":"e_1_3_9_21_2","first-page":"23","volume-title":"Poster Number 42: Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US","author":"Sandoval-Leon A","year":"2025","unstructured":"Sandoval-Leon A, O\u2019Shaughnessy J, Liepa A, et al. Poster Number 42: Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US. 42nd Annual Miami Breast Cancer Conference - Abstracts 39:23-24, 2025"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106021"},{"key":"e_1_3_9_23_2","volume-title":"FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy","author":"Center for Drug Evaluation and Research","year":"2023","unstructured":"Center for Drug Evaluation and Research: FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy. US FDA. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy"},{"key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10238-023-01261-4","article-title":"Developing questions to assess and measure patients\u2019 perceived survival benefit from adjuvant endocrine therapy in breast cancer: A mixed methods pilot study","volume":"24","author":"Tawfik B","year":"2024","unstructured":"Tawfik B, Jacobson K, Brown-Glaberman U, et al: Developing questions to assess and measure patients\u2019 perceived survival benefit from adjuvant endocrine therapy in breast cancer: A mixed methods pilot study. Clin Exp Med 24:36, 2024","journal-title":"Clin Exp Med"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531"},{"key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1158\/1538-7445.AM2023-4364","article-title":"Abstract 4364: Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+\/HER2-, node-positive, high-risk, early breast cancer","volume":"83","author":"Talwar A","year":"2023","unstructured":"Talwar A, Deshmukh A, Trivedi M, et al: Abstract 4364: Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+\/HER2-, node-positive, high-risk, early breast cancer. Cancer Res 83:4364, 2023 (suppl 7)","journal-title":"Cancer Res"},{"key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cancers16122168","article-title":"Social determinants of health and other predictors in initiation of treatment with CDK4\/6 inhibitors for HR+\/HER2\u2212 metastatic breast cancer","volume":"16","author":"Goyal RK","year":"2024","unstructured":"Goyal RK, Candrilli SD, Abughosh S, et al: Social determinants of health and other predictors in initiation of treatment with CDK4\/6 inhibitors for HR+\/HER2\u2212 metastatic breast cancer. Cancers 16:12, 2024","journal-title":"Cancers"},{"key":"e_1_3_9_28_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.501","article-title":"Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)","volume":"41","author":"Hamilton EP","year":"2023","unstructured":"Hamilton EP, Kim JH, Eigeliene N, et al: Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol 41, 2023 (suppl 16; abstr 501)","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"P2-08-12","DOI":"10.1158\/1538-7445.SABCS19-P2-08-12","article-title":"Abstract P2-08-12: Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+,HER2- metastatic breast cancer","volume":"80","author":"Carter GC","year":"2020","unstructured":"Carter GC, Sheffield KM, Gossai A, et al. Abstract P2-08-12: Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+,HER2- metastatic breast cancer. Cancer Res 80:P2-08-12, 2020 (suppl 4)","journal-title":"Cancer Res"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1923468"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.44517"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25485"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13964"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500"},{"key":"e_1_3_9_35_2","volume-title":"FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer","author":"Center for Drug Evaluation and Research","year":"2024","unstructured":"Center for Drug Evaluation and Research: FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer. US FDA. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ribociclib-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-early-high-risk"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:20:23Z","timestamp":1775143223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/OA-25-00076"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00076","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e2500076"}}